Full Event Guide
Download the Full Event Guide for the 4th Liquid Biopsy for Precision Oncology East Coast
Uniting key stakeholders from the likes of Amgen, Takeda, AstraZeneca, AbbVie, Replicate Bioscience and more, this is your opportunity to take part in 2-days dedicated to learn how experts are advancing liquid biopsy in ADCs, personalized cancer vaccines, RAS-mutant therapies, CTCs, rare disease and more.
A Snapshot of Companies Already Attending...
Having trouble downloading the brochure? Email us and we’ll send you a copy.
Agenda Sneak Peek:
Driving Early Intervention & Personalised Monitoring
Explore the latest data from biopharma showcasing how ctDNA analysis is delivering real-world impact, revolutionizing how patients are monitored and enabling earlier, more informed intervention – insights from Geneos Therapeutics, Takeda and more.
Refining Dosing Strategies
Explore how ctDNA is enabling dynamic dose adjustment to reduce toxicity, sustain efficacy & personalize treatment – with insights from Repare Therapeutics, Johnson & Johnson and BLOODPAC
Advancing MRD as a Surrogate Endpoint
Unpack how MRD is reshaping endpoint strategy in hematology trials, and gain insight into the regulatory roadmap enabling this shift, unlocking faster and more meaningful readouts to get your drug to market faster, insights from AstraZeneca, FNIH, Weill Cornell and more
Enhancing ADC Safety, Efficacy & Precision
Leverage liquid biopsy insights to drive safer, more targeted antibody-drug conjugate development, boosting precision, efficacy and safety, and ultimately patient outcomes, insights from AbbVie, BrickBio, GSK and more
Audience Breakdown:
Official Partners:
Program Partners
Panel Partners
Need More Reasons to Attend? Hear From Past Attendees:
“The quality of speakers was great! I really learned something new each time.”
Past Attendee, Associate Director – PTM Strategic Innovations, Takeda
“The intimacy of the event enables meaningful meeting connections”
Director of Technical Sales, BioIVT
“Well-organized summit, with a diverse agenda, mixing academia, non-profit, platform developers and biotech/pharma experts.”
Past Attendee, Executive Director, Oncology & Translational Lead, Pfizer